Despite vast use across several therapeutic pathways, there has been minimal effort devoted to improving lithium formulation to decrease toxicity risk and improve the patient experience. Trelkin is working to expand on a novel formulation for controlled lithium delivery discovered by Dr. Ariel Furst at MIT, by placing a lithium loaded shell onto a microparticle core. 

Using this method, Trelkin is setting out to demonstrate therapeutically relevant concentrations can be achieved for far longer than today's standard of care, while also avoiding  toxic concentration spikes and reducing adverse renal impacts. 

Trelkin is expanding on this tunable platform to optimize drug delivery and offer prescribers and patients a greater array of options for precise therapies.